J Van Kampen1, M Katz. Show Affiliations » 1. Department of Psychiatry, University of Toronto, ON, Canada.
Abstract
Entities: Disease
Mesh: See more » AdolescentAntipsychotic Agents/therapeutic useBenzodiazepinesCannabis/adverse effectsChronic DiseaseDose-Response Relationship, DrugFemaleHallucinogens/adverse effectsHumansIllicit Drugs/adverse effectsN-Methyl-3,4-methylenedioxyamphetamine/adverse effectsOlanzapinePirenzepine/analogs & derivativesPirenzepine/therapeutic usePsilocybin/adverse effectsPsychoses, Substance-Induced/drug therapyPsychoses, Substance-Induced/etiologyPsychoses, Substance-Induced/psychologySerotonin Agents/adverse effectsSerotonin Uptake Inhibitors/therapeutic useTreatment Outcome
Substances: See more » Antipsychotic AgentsHallucinogensIllicit DrugsSerotonin AgentsSerotonin Uptake InhibitorsBenzodiazepinesPsilocybinPirenzepineN-Methyl-3,4-methylenedioxyamphetamineOlanzapine
Year: 2001 PMID: 11815690 DOI: 10.1176/appi.psy.42.6.525
Source DB: PubMed Journal: Psychosomatics ISSN: 0033-3182 Impact factor: 2.386